[Preprint] Estudo observacional mostra que a dose única da vacina da Johnson & Johnson tem eficácia de 76,7% em evitar infecção por SARS-CoV-2.
13 Mai, 2021 | 10:15hReal-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19 – The Lancet
Comentário no Twitter
One of the first studies to assess real-world effectiveness of the J&J 1-dose vaccine, matches Phase 3 clinical trial, at 77%https://t.co/3YgcML9YSh @MayoClinic @MayoClinicHS preprint pic.twitter.com/XOjQlUaHK2
— Eric Topol (@EricTopol) May 11, 2021